Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Synergy in Cystic Fibrosis Therapies: Targeting SLC26A9.

International journal of molecular sciences - 2 Dec 2021

Pinto Madalena C, Quaresma Margarida C, Silva Iris A L, Railean Violeta, Ramalho Sofia S, Amaral Margarida D

Abstract excerpt

SLC26A9, a constitutively active Cl- transporter, has gained interest over the past years as a relevant disease modifier in several respiratory disorders including Cystic Fibrosis (CF), asthma, and non-CF bronchiectasis. SLC26A9 contributes to epithelial Cl- secretion, thus preventing mucus obstruction under inflammatory conditions. Additionally, SLC26A9 was identified as a CF gene modifier, and its polymorphisms...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Aminopyridines
Share to Antiporters

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzodioxoles

Share to Bronchi

Share to Organ Culture Techniques

Share to Sulfate Transporters

Share to Zonula Occludens-1 Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 34884866
DOI: 10.3390/ijms222313064
PMCID: PMC8658147

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synergy in Cystic Fibrosis Therapies: Targeting SLC26A9.PMID 34884866Read ↗

The revolution of personalized pharmacotherapies for cystic fibrosis: what does the future hold?Semantic proximity Read ↗

SLC26A9 stimulates CFTR expression and function in human bronchial cell linesSemantic proximity Read ↗

Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung diseaseSemantic proximity Read ↗

A novel SLC26A9 inhibitor, S9-A13, reveals a minor contribution of SLC26A9 to constitutive airway chloride secretionSemantic proximity Read ↗

Targeting ion channels in cystic fibrosis.Semantic proximity Read ↗

The solute carrier family 26 member 9 modifies rapidly progressing cystic fibrosis associated with homozygous F508del CFTR mutation.Semantic proximity Read ↗

Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics.Semantic proximity Read ↗

The Solute Carrier Family 26 Member 9 Is a Modifier of the Rapidly Progressing Cystic Fibrosis Associated with F508del CFTR MutationsSemantic proximity Read ↗

Ion Channel Modulators in Cystic Fibrosis.Semantic proximity Read ↗

CFTR dysfunction in cystic fibrosis and chronic obstructive pulmonary disease.Semantic proximity Read ↗

SLC26A9-mediated chloride secretion prevents mucus obstruction in airway inflammation.Semantic proximity Read ↗

Theratyping of the Rare CFTR Genotype A559T in Rectal Organoids and Nasal Cells Reveals a Relevant Response to Elexacaftor (VX-445) and Tezacaftor (VX-661) Combination.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.